Progyny, Inc. Stock Price, News & Analysis

Progyny (Nasdaq: PGNY) announced a global expansion of benefits to include pregnancy, postpartum, and menopause programs, available to employers starting January 1, 2026. The offerings complement Progyny’s existing global fertility and family building services to provide an integrated continuum across life stages.

Key features include personalized Global Care Advocates, a curated evidence-based knowledge center, country-specific navigator support, and a GDPR-compliant benefits platform. The program supports employees in more than 127 countries with multilingual capabilities.

Transcarent (PGNY) expanded its Experience Store on October 21, 2025 by adding three women’s health partners — Maven Clinic, Midi Health, and Progyny — to existing partners Carrot and Kindbody, aiming to centralize fertility, family-building, perimenopause and menopause care for Members.

The WayFinding™ generative-AI experience offers single sign-on, consolidated reporting, and measurable outcomes; Transcarent cites 7.6x more referrals to women’s health and a 10–20% increase in point-solution utilization when fragmentation is reduced.

Progyny (Nasdaq: PGNY) announced that CEO Pete Anevski was named a Champion for Women’s Health by the World Economic Forum and the Global Alliance for Women’s Health on October 7, 2025.

Anevski joins a global community of leaders committed to advocacy, policy, research, innovation, and investment to close care gaps in women’s health. Progyny said Chief Medical Officer Dr. Janet Choi also participated in GAWH workgroups on maternal health and women’s health science. The company said it will engage in Forum platforms and initiatives to promote research and scalable solutions across governments, investors, and industries worldwide.

Progyny (NASDAQ: PGNY), a women's health and family building solutions provider, reported strong Q2 2025 results with revenue of $332.9 million, up 9.5% year-over-year. Excluding a large transitioning client, revenue growth was 18%. The company achieved net income of $17.1 million ($0.19 per diluted share) and Adjusted EBITDA of $57.9 million.

Key metrics include 542 fertility clients (up from 463 YoY), 16,938 ART cycles performed, and 6.74 million average members. The company generated strong cash flow of $55.5 million in Q2 and a record $105.3 million in H1 2025.

Progyny raised its full-year 2025 guidance, projecting revenue of $1.235-1.270 billion (15.1-18.5% growth excluding the transitioning client) and net income of $52.3-58.9 million.

Progyny (Nasdaq: PGNY), a leader in women's health and family building solutions, released a national study revealing significant disparities in workplace health benefits. While 81% of HR leaders claim commitment to women's health, only 52% of working women find their benefits make healthcare affordable.

The research highlights critical gaps: while 83% of women prioritize menopause-related benefits, only 12% report adequate employer support. Additionally, 24% of women abandon using benefits due to complexity, and 83% of women and 88% of employers agree that centralized support would improve effectiveness. The study emphasizes the need for comprehensive women's health programs, as 69% of benefit managers consider these benefits crucial for attracting and retaining younger talent.

Progyny (Nasdaq: PGNY) has announced a strategic partnership with ŌURA, a leading smart ring manufacturer, to enhance women's health monitoring and care from preconception through menopause. The collaboration will integrate ŌURA's wearable technology data into Progyny's healthcare ecosystem starting in early 2026.

The partnership aims to provide comprehensive health tracking capabilities, including sleep patterns, cycle insights, cardiovascular health, and stress levels. This data integration will enable earlier risk identification and support various health goals, particularly in fertility planning and menopause management. The initiative will be available to Progyny's client base, including employers and health plans.

Progyny (NASDAQ: PGNY), a leader in women's health and family building solutions, has secured a new $200 million revolving credit facility maturing on July 1, 2030. The undrawn facility enhances the company's operational and financial flexibility, though there are no immediate plans for its use.

The company anticipates Q2 2025 financial results to exceed previous guidance due to favorable member activity. Revenue, Adjusted net income, and Adjusted EBITDA are expected to surpass the ranges provided in May. Progyny will report detailed Q2 2025 results on August 7, 2025, after market close.

The company maintains its capital priorities, including potential stock repurchases, product portfolio expansion, investments in distribution channels, and strategic acquisitions.

Progyny (NASDAQ: PGNY), a leader in women's health solutions, has announced the addition of pelvic floor therapy to its comprehensive healthcare offerings. The expansion includes partnerships with Origin for in-person and virtual physical therapy, and Hinge Health for digital care solutions.

The initiative addresses a significant healthcare gap, as one in three women experience pelvic floor issues, with 20% requiring surgery. The program aims to provide early intervention and comprehensive care through specialty-trained providers, potentially reducing the $20 billion annual healthcare costs associated with urinary incontinence alone.

Progyny (NASDAQ: PGNY), a leading women's health and family building solutions provider, has joined Amazon's Health Benefits Connector program as its first comprehensive women's health provider. This collaboration enables eligible Amazon customers to discover and enroll in Progyny's fertility, family building, and menopause benefits through their employers or health plans. Progyny currently serves over 530 employers and health plans, reaching more than 6.7 million lives with its clinically integrated care model. The partnership aims to address the issue that nearly 25% of U.S. adults face in understanding their available health benefits. Through Amazon's platform, users can easily verify their Progyny coverage and access personalized support with just a few clicks.